It has been revealed that, in breast cancer, miR-30a suppresses EMT progress by targeting ZEB2 34, Slug 35, Snail 36, ITGB3 37, and ROR1 38, and inhibits CSC properties by targeting Nanog 39, and AVEN 40. This evidence concerns the gene ITGB3 and breast carcinoma.